American Brachytherapy Society highlights benefits of new skin cancer treatment

A new treatment for non-melanoma skin cancer has been highlighted at an annual meeting.

A poster presentation at the 2013 American Brachytherapy Society Annual Meeting has highlighted the advantages of a new treatment for non-melanoma skin cancer.
Positive data on the Xoft Axxent Electronic Brachytherapy System from iCad Inc supports it as a potential way to treat hard-to-reach lesions, such as those on the tip of the nose, eyelids and behind the ear.
Dr Ajay Bhatnagar, of the University of Pittsburgh, explained that the data demonstrated good cosmetic results, low toxicity and no recurrence at one year.
He also said it allowed users to "drastically" reduce treatment time, which is particularly positive for elderly patients.
Chief executive of iCad Ken Ferry said: "Increased evidence of improved clinical outcomes combined with shorter treatment times and the system's mobility are contributing to the rapid adoption of the Xoft System."
Non-melanoma skin cancer is the most common form of cancer in humans and can be identified as either basal cell carcinoma or squamous cell carcinoma.